Cyn3rgy
Cyn3rgy Research is a founder-owned clinical trial site in Gresham, Oregon, conducting Phase 2b-4 studies for pharmaceutical sponsors with a focus on pediatric and adult indications including ADHD, pneumococcal disease, acne, and functional constipation.
- Company typePrivate
- Founded2009
- HeadquartersGresham, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
What Cyn3rgy does
Cyn3rgy Research is a privately-held, founder-owned clinical research site (CRO site) headquartered in Gresham, Oregon, founded in 2009. The company conducts Phase 2b through Phase 4 clinical trials on behalf of pharmaceutical and biotech sponsors, with a deliberate specialization in pediatric indications alongside adult studies. As of late 2023, five trials are actively enrolling, including SPN-812 in preschool-age ADHD, CABTREO in pediatric acne vulgaris, Plecanatide in pediatric functional constipation, pneumococcal disease vaccine candidates in infants, and a CareSuperb COVID-19/Flu A&B/RSV diagnostic sample study; several additional studies (Fucithalmic, MenABCWY, Varivax, variant-adapted BNT162b2, VAX-31) are listed as completed or inactive.
The business operates on a project-based revenue model typical of independent clinical trial sites, generating income from per-patient fees, milestone payments, and study conduct contracts negotiated with study sponsors. Participants are compensated for time and travel on a per-study basis, with specific amounts determined per trial. Cyn3rgy's distribution is direct: patients are recruited through the company website (cyn3rgy.com), downloadable vaccine and clinical trial education resources, and referrals from local healthcare providers. Community outreach and engagement with local and statewide public health initiatives round out the recruitment infrastructure.
The team is small (six named staff) and led by two founding partners — Dr. Frank Calcagno (Medical Director, 25 years of PI experience) and Curt A Heiting (President, 35 years of industry experience including 17+ in clinical trial delivery) — supported by two sub-investigators with pediatric research expertise, a research manager, and a clinical research coordinator. Cyn3rgy holds no patents, has no disclosed funding rounds, no parent company, no M&A history, and no disclosed partnerships or alliances. Technology is limited to standard GCP-compliant trial conduct and clinical research methodologies; no proprietary platform, software, or AI/ML capabilities are indicated.
Cyn3rgy firmographics
Firmographics- Name
- Cyn3rgy
- Legal name
- Cyn3rgy Research
- Website
- https://cyn3rgy.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cyn3rgy Research is a founder-owned clinical trial site in Gresham, Oregon, conducting Phase 2b-4 studies for pharmaceutical sponsors with a focus on pediatric and adult indications including ADHD, pneumococcal disease, acne, and functional constipation.
- Ownership category
- akta.pro rank
Cyn3rgy industry classification
Industry- Product category
- Clinical Research Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- Clinical Trial Site Operations & Study CoordinationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Clinical Trial Services & Site Management (SMO)
Keywords
Where Cyn3rgy is headquartered
LocationHeadquarters
- HQ city
- Gresham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cyn3rgy business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Distribution channels2 records
Marketing channels4 records
Cyn3rgy product offering
Product offeringCore offering
Cyn3rgy Research operates a clinical research site that conducts GCP-compliant Phase 2b through Phase 4 clinical trials on behalf of pharmaceutical and biotech sponsors, recruiting pediatric and adult participants across therapeutic areas including ADHD, pneumococcal disease, acne, functional constipation, and diagnostic testing. The company serves as an investigator site executing sponsor-funded protocols, providing protocol implementation, patient recruitment and retention, data collection, and regulatory-compliant study conduct.
Product overview
Cyn3rgy is a clinical research organization offering a unified platform of clinical trial services focused on advancing medical treatments and therapies for both pediatric and adult populations. The company's service portfolio consists of five actively enrolling clinical studies: Diagnostic Sample Studies (COVID-19/Flu/RSV antigen testing), ADHD Clinical Trial (SPN-812 in preschoolers), Pneumococcal Disease Vaccine Clinical Trials (multiple vaccine candidates in infants), Acne Clinical Trials (CABTREO topical gel in pediatric patients), and Functional Constipation Clinical Research (Plecanatide in children/adolescents). Cyn3rgy also lists additional completed or inactive studies including Fucithalmic eye drops, MenABCWY vaccine, Varivax, Variant-Adapted BNT162b2 RNA-Based vaccine, Multivalent Pneumococcal Conjugate Vaccine, 21-Valent Pneumococcal Conjugate Vaccine, and VAX-31 vaccine trials.
Differentiator
Problem solved
Functional benefit
Products and services
- Diagnostic Sample Studies Clinical study evaluating the performance of the CareSuperb COVID-19/Flu A&B/RSV antigen combo test, where qualifying subjects self-take a swab test in the clinic. Conducted for diagnostic test sponsors.
- ADHD Clinical Trial Phase 4, randomized, double-blind, multicenter, placebo-controlled, parallel-group study evaluating the efficacy and safety of SPN-812 in preschool-age children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Pneumococcal Disease Vaccine Clinical Trials Clinical trials investigating broader coverage of Pneumococcal Disease in healthy infants, studying newer generation Pneumococcal Disease Vaccines including multivalent and 21-valent conjugate vaccine candidates.
- Acne Clinical Trials 12-Week, Phase 4, Open-Label Study assessing safety, pharmacokinetics, and treatment effect of CABTREO (Clindamycin Phosphate 1.2%, Adapalene 0.15%, and Benzoyl Peroxide 3.1%) Topical Gel in pediatric participants ages 9 to 11 years, 11 months with acne vulgaris.
- Functional Constipation Clinical Research Phase 2b, randomized, double-blind, placebo-controlled, parallel group study evaluating the efficacy and safety of Plecanatide in children and adolescents age 6 to under 18 years with Functional Constipation.
Companies that use Cyn3rgy
Customer profileSegments2 records
Ideal customer profiles3 records
Cyn3rgy technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cyn3rgy partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Cyn3rgy competitors and assessment
Company assessmentBroad incumbents
- Medpace: Mid-to-large full-service CRO running Phase 1-4 trials across all major therapeutic areas. Comparable as a clinical trial delivery organization, though at far greater scale and with sponsor/CRO services rather than site services.
- Velocity Clinical Research: Large multi-site clinical trial site network with broad therapeutic coverage including vaccines, dermatology, GI, and CNS indications. Comparable to Cyn3rgy in service offering (multi-specialty clinical trial site operations) but at vastly greater scale.
Direct peers
- Altus Research: Clinical research site organization conducting trials across multiple therapeutic areas. Comparable in being an independent site operator running diverse Phase 2-4 studies.
- Meridien Research: Independent clinical research site operator running trials in dermatology, GI, vaccines, and other indications. Comparable as an independent site competing for similar sponsor protocols.
- Benchmark Research: Independent clinical research site network operating across multiple U.S. locations running vaccine, dermatology, and CNS trials. Directly comparable as an independent multi-site operator.
- Accel Research Sites: Multi-therapeutic clinical research site network running Phase 2-4 trials across CNS, dermatology, vaccines, and GI. Direct competitor to Cyn3rgy in the multi-specialty independent site category, though larger.
Emerging players
- Javara Research: Integrated clinical research organization embedded within healthcare provider systems. Comparable in operating as a community/site-based trial delivery business with multi-therapeutic coverage.
- Circuit Clinical: Tech-enabled clinical trial site network focused on community-based research participation. Comparable in targeting community-based trial recruitment, with a more technology-forward operating model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Cyn3rgy social profiles
Digital presenceCyn3rgy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyn3rgy leadership team
Management profileNumber of profiles
Profiles6 records
Cyn3rgy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyn3rgy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyn3rgy
What does Cyn3rgy do?
Cyn3rgy Research operates a clinical research site that conducts GCP-compliant Phase 2b through Phase 4 clinical trials on behalf of pharmaceutical and biotech sponsors, recruiting pediatric and adult participants across therapeutic areas including ADHD, pneumococcal disease, acne, functional constipation, and diagnostic testing. The company serves as an investigator site executing sponsor-funded protocols, providing protocol implementation, patient recruitment and retention, data collection, and regulatory-compliant study conduct.
Is Cyn3rgy a public or private company?
Cyn3rgy is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cyn3rgy founded?
Cyn3rgy was founded in 2009. It employs 1 to 10 people.
Where is Cyn3rgy based?
Cyn3rgy is headquartered in Gresham, United States, in the North America region.
Who are Cyn3rgy's main competitors?
Broad incumbents on record are Medpace and Velocity Clinical Research. Direct peers are Altus Research, Meridien Research, Benchmark Research and Accel Research Sites. Emerging players are Javara Research and Circuit Clinical.
Does Cyn3rgy have an API?
No public API is recorded for Cyn3rgy.
What industry is Cyn3rgy in?
Cyn3rgy's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8731.